Medical therapy for inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 13, Issue 4, 1997, Pages 307-311

  Feagan, Brian G ^a   McDonald, John W D ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BUDESONIDE; ERYTHROPOIETIN; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; METHOTREXATE; PURINE DERIVATIVE; SALAZOSULFAPYRIDINE; STEROID; VITAMIN D;

ANEMIA; ANTIBIOTIC THERAPY; CROHN DISEASE; DIET THERAPY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NUTRITION; OSTEOPENIA; REMISSION; SHORT SURVEY; STEROID THERAPY; ULCERATIVE COLITIS;

EID: 0030809351     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199707000-00005     Document Type: Short Survey

References (33)

1. Feagan BG, McDonald JW, Koval JJ: Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trials. Gastroenterology 1996, 110:275-283.
2. Feagan BG. Oral budesonide therapy for ulcerative colitis: a topical tale. Gastroenterology 1996, 110:2000-2002.
3. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson L, Perrson, T, and the Canadian Inflammatory Bowel Disease Study Group: Oral budesonide for active Crohn's disease. N Engl J Med 1994, 331:836-841.
4. Lemann M, Galian A, Rutgeerts P, Van Heuverzwijn R, Cortot A, Viteau JM, Elewaut A, Belaiche J, Froguel E, Modigliani R. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995, 9:557-562.
5. Lofberg R, Danielsson A, Suhr O, Nilsson A, Schioler R, Nyberg A, Hultcrantz R, Kollberg B, Gillberg R, Willen R, et al.: Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996, 110:1713-1718. Oral budesonide formulated to release distally was effective in ulcerative colitis, representing a promising new approach.
6. Hawthorne AB Logan RFA, Hawkley CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE: Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992, 305:20-22
7. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841-1845.
8. Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, Ron Y, Reisfeld I, Broide E, Lavy A, et al.: Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996, 110:1416-1421. Oral methotrexate in a dose of 12.5 mg weekly was ineffective for inducing remission in patients with chronic UC.
9. Feagan B, McDonald JWD, Rochon J, Fedorak R, Irvine EJ, Sutherland L Steinhart H, Gillies R: Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995, 332:292-297.
10. Kozarek R: Methotrexate and ulcerative colitis: wrong drug? Wrong dose? Or wrong disease? [editorial; comment] Gastroenterology 1996, 110:1652-1656. Suggests reasons why the results of this trial were negative, whereas a previous study in Crohn's disease yielded positive results.
11. Fockens P, Mulder CJ, Tytgat GN, Blok P, Ferwerda J, Meuwissen SG, Tuynman HA, Dekker W, Gasthuis K, van Hees PA: Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Eur J Gastroenterol Hepatol 1995, 7:1025-1030.
12. Ardizzone S, Petrillo M, Molteni P, Desideri S, Porro GB: Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis: a double-blind study. J Clin Gastroenterol 1995, 21:287-289.
13. Kam L, Cohen H, Dooley C, Rubin P, Orchard J: A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 1996, 91:1338-1342.
14. The Mesalamine Study Group: An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 1996, 124:204-211. Placebo-controlled RCT demonstrating maintenance of remission by oral mesalamine compared with placebo.
15. Hanauer SB: Drug therapy: inflammatory bowel disease. N Engl J Med 1994, 334:841-848.
16. Sutherland LR, May GR, Shaffer EA: Sulfasalazine revisited: a meta analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993, 118:540-549.
17. Kapur KC, Williams GT, Allison MC: Mesalazine induced exacerbation of ulcerative colitis. Gut 1995, 37:838-339.
18. Gujral N, Friedenberg F, Friedenberg J, Gabriel G, Kotler M, Levine G: Pleuropericarditis related to the use of mesalamine. Dig Dis Sci 1996, 41:624-626. Demonstrates that newer mesalamine compounds may cause significant toxicity.
19. Bitton A, Peppercorn MA, Hanrahan JP, Upton MP: Mesalamine-induced lung toxicity. Am J Gastroenterol 1996, 91:1039-1040. Demonstrates that newer mesalamine compounds may cause significant toxicity.
20. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Makhjian H, Greenberger N, Kelly M: Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991, 32:1071-1075
21. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C: An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996, 91:328-332. First controlled evaluation of metronidazole plus ciprofloxacin versus steroid therapy; the study is too small to support the conclusion of an equivalent response to glucocorticoid therapy.
22. Messori A, Trallori G, Dalbasio G, Milla M, Vannozzi G, Pacini F: Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis. Gastroenterology 1996, 31:267-272. This meta-analysis confirms that steroids are more effective than dietary therapy and includes a sensitivity analysis, making it very unlikely that negative unpublished studies could materially alter the result.
23. Griffiths AM, Ohlsson A, Sherman PM, Sutherland, LR: Meta analysis of enterai nutrition as primary treatment of active Crohn's disease. Gastroenterology 1995, 108:1056-1067.
24. Pearson DC May GR Fick GH and Sutherland LR: Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 1995, 123:132-142.
25. Feagan B, McDonald JWD, Archambault A, Fedorak R, Groll A, Irvine EJ, Kinnear D, Laupacis A, Rochon J, Saibil F, Valberg B: Low dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994, 330:1846-1851.
26. Jewell D, Lennard-Jones J, and the Cyclosporin Study Group of Great Britain and Ireland: Oral cyclosporine for chronic active Crohn's disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 1994, 6:499-505.
27. Wood AJ, Feutren G, Smith Pr, Wood AJ, Feutren G, Smith PR: European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. Gastroenterology 1995, 109:774-782.
28. Mahdi G, Israel DM, Hassall E: Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children. Am J Gastroenterol 1996, 91:1355-1359
29. Schreiber S, Howaldt S, Schnoor M, Nikolaus S, Bauditz J, Gasche C, Lochs H, Raedler A: Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease [see comments]. N Engl J Med 1996, 334:619-623. This RCT demonstrates that anemia in inflammatory bowel disease that is refractory to iron and vitamins responds to erythropoietin injections.
30. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A: Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995, 7:609-614
31. Minne HW, Quan J, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Minne HW, Quan J, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase 111 Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443.
32. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R: A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37:674-678.
33. Becktel JM, Best WR, Kern F Jr, Singleton JW, Becktel JM, Best WR, Kern F Jr, Singleton JW: National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979, 77:847-869.